Thermotropic phase behavior of DPPC liposome systems in the presence of the anti-cancer agent 'Ellipticine'

被引:9
作者
Cavalcanti, Leide P.
Torriani, Iris L.
机构
[1] Synchrotron Light Natl Lab, LNLS, BR-13084971 Campinas, SP, Brazil
[2] Univ Estadual Campinas, UNICAMP, Inst Phys, BR-13083970 Campinas, SP, Brazil
来源
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS | 2006年 / 36卷 / 01期
关键词
liposome; membrane; DPPC; Ellipticine; X-ray diffraction; drug delivery;
D O I
10.1007/s00249-006-0077-3
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
This letter presents our first results on the structural changes in DPPC multilamellar vesicles dispersed in water in the presence of the anti-cancer agent Ellipticine. The thermotropic phase transitions of the lamellar packing inside lipid vesicles were characterized in situ by small angle X ray diffraction. The results lead to the determination of a critical concentration value for drug loading on the vesicle system around 4% molar fraction of Ellipticine, an indication of the localization of the drug in the alkyl chains and the influence of the drug on the decreasing rate of the bilayer period after the main phase transition.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 12 条
[1]   A SMALL-ANGLE X-RAY-SCATTERING WORKSTATION FOR NATIONAL LABORATORY FOR SYNCHROTRON LIGHT [J].
BERNARDES, LA ;
TOLENTINO, H ;
RODRIGUES, ARD ;
CRAIEVICH, A ;
TORRIANI, I .
REVIEW OF SCIENTIFIC INSTRUMENTS, 1992, 63 (01) :1065-1067
[2]   Prehistory in the pretransition range of dipalmitoylphosphatidylcholine/water system [J].
Bota, A ;
Kriechbaum, M .
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 1998, 141 (03) :441-448
[3]   Lipid model membranes for drug interaction study [J].
Cavalcanti, LP ;
Konovalov, O ;
Torriani, IL .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2006, 35 (05) :431-438
[4]   The small-angle X-ray scattering beamline of the Brazilian Synchrotron Light Laboratory [J].
Kellermann, G ;
Vicentin, F ;
Tamura, E ;
Rocha, M ;
Tolentino, H ;
Barbosa, A ;
Craievich, A ;
Torriani, I .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1997, 30 (02) :880-883
[5]  
KOHN KW, 1975, CANCER RES, V35, P71
[6]   Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics [J].
Mathé, G ;
Triana, K ;
Pontiggia, P ;
Blanquet, D ;
Hallard, M ;
Morette, C .
BIOMEDICINE & PHARMACOTHERAPY, 1998, 52 (09) :391-396
[7]  
SAINSBURY M, 1990, CHEM ANTITUMOR AGENT, P410
[8]   HIGH-FIELD NMR AND RESTRAINED MOLECULAR MODELING STUDIES ON A DNA HETERODUPLEX CONTAINING A MODIFIED APURINIC ABASIC SITE IN THE FORM OF COVALENTLY-LINKED 9-AMINOELLIPTICINE [J].
SINGH, MP ;
HILL, GC ;
PEOCH, D ;
RAYNER, B ;
IMBACH, JL ;
LOWN, JW .
BIOCHEMISTRY, 1994, 33 (34) :10271-10285
[9]   The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts [J].
Stiborová, M ;
Bieler, CA ;
Wiessler, M ;
Frei, E .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (12) :1675-1684
[10]   STRUCTURE AND POLYMORPHISM OF HYDROCARBON CHAINS OF LIPIDS - STUDY OF LECITHIN-WATER PHASES [J].
TARDIEU, A ;
LUZZATI, V ;
REMAN, FC .
JOURNAL OF MOLECULAR BIOLOGY, 1973, 75 (04) :711-&